CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...

Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved ...

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended Senate Republican tax bill passes ‘SALT’ ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...